Media & Investors

  • home
  • Media and Investor Information

Media and Investor Information

Financials

After a successful 2016/17 we will grow by approximately 15 % in terms of turnover in the financial year 2017/18. In terms of EBIT, we are planning for the same or a slightly higher result as in the past year.

More facts & figures

Coming events

DateEvent
Place
9 November 2017 Media conference and analysts’ presentation of the semiannual figures 2017/18 Zurich
24 May 2018 Media conference and analysts’ presentation of the
annual figures 2017/18
Burgdorf

Investor agenda

Latest News

Ypsomed to separate from Insulet and extend its portfolio with an own patch pump in the mid-term

Burgdorf, 21 July 2017, 7 a.m. – Ypsomed has been the exclusive distributor for the mylife OmniPod® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife YpsoPod® insulin pump in the mid-term.

Ypsomed accelerates growth significantly

Burgdorf, 24 May 2017, 7.00 a.m. – In the financial year 2016/17, the Ypsomed Group generated consolidated sales of CHF 389.6 million (previous year: CHF 336.9 million). Compared with the previous year, this represents an increase in sales of 15.6%. The operating results (EBIT) also increased by 24.4% compared to the previous year, from CHF 44.4 million to CHF 55.3 million. Profitability at the EBIT level has now risen to 14.2% (previous year: 13.2%). Compared with the previous year, the net profits were raised by 29.1% from CHF 35.8 million to CHF 46.2 million. Some demanding tasks lie ahead for the coming financial year, but Ypsomed remains confident and again expects a growth in sales of approximately 15% for the financial year 2017/18.

Ypsomed expands to more countries

Ypsomed expands to more countries

Burgdorf, 10 May 2017, 7 a.m. – Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.

Ypsomed’s reusable YpsoPen introduced in Malaysia by Biocon

Burgdorf, 12 April 2017, 7.00 a.m. – Ypsomed has collaborated with Biocon, an emerging global biopharmaceutical company headquartered in India, to customise its reusable YpsoPen for use with Biocon’s insulin cartridges. This customised reusable pen will be marketed by Biocon as INSUPen Pro™ in Malaysia.

Ypsomed opens a new production line in Solothurn

Burgdorf, 25 January 2017, 7.00 a.m. – Following 18 months of industrialisation, Ypsomed opened its new production line in their Solothurn works and will have created over 50 new jobs on final expansion. The inauguration was held yesterday with representatives of local commerce and guests from politics in attendance.